Table 1.

Correlation among Clinicopathological Status between the Expression of lncRNA CILA1 and p-β-Catenin in TSCC Patients

Characteristics	lncRNA CILA1 (%)		p Value	p-β-Catenin (%)		p Value
	No. of High Expression	No. of Low Expression		No. of High Expression	No. of Low Expression
Sex
Male	48 (50.1)	46 (49.9)	0.976	43 (45.7)	51 (54.3)	0.224
Female	31 (50.8)	30 (49.2)	0.976	34 (55.7)	27 (44.3)	0.224
Age
<50 years	22 (52.4)	20 (47.6)	0.830	19 (45.2)	23 (54.8)	0.500
≥50 years	57 (50.4)	56 (49.6)	0.830	58 (51.3)	55 (48.7)	0.500
Node Metastasis
N0	30 (39.5)	46 (60.5)	0.005	31 (40.8)	45 (59.2)	0.03
N+	49 (62.0)	30 (38.0)	0.005	46 (58.2)	33 (41.8)	0.03
Clinical Stage
III	28 (38.9)	44 (61.1)	0.005	27 (37.5)	45 (62.5)	0.002
IV	51 (61.4)	32 (38.6)	0.005	50 (60.2)	33 (39.8)	0.002
Status
Survival	13 (37.1)	22 (62.9)	0.000	15 (42.9)	20 (57.1)	0.011
Death	66 (55.0)	54 (45.0)	0.000	62 (51.7)	58 (48.3)	0.011
Cisplatin
Sensitive	24 (35.3)	44 (64.7)	0.005	24 (35.3)	44 (64.7)	0.004
Non-sensitive	55 (63.2)	32 (36.8)	0.005	53 (60.9)	34 (39.1)	0.004